Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KNOLL SYNTHROID CAMPAIGN MUST REFLECT "MATERIAL INFORMATION" IN UNPUBLISHED ARTICLE, FDA TELLS COMPANY: OPENING VOLLEY IN 1997 DEBATE ON JOURNAL REPRINTS?

Executive Summary

Knoll's dissemination of a 1993 article on Synthroid and competing levothyroxine products is misleading because the company has not disclosed "material information" in its possession about the issue, FDA charges in a Nov. 7 letter to the company.
Advertisement

Related Content

GSK Faces New York Suit Over Paxil: Publish Or Punish?
GSK Faces New York Suit Over Paxil: Publish Or Punish?
Advertisement
UsernamePublicRestriction

Register

PS029188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel